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mg/m2 (IRMA 1, 2, 3, 5) or Cetuximab 400 mg/m2 (IRMA 4). A 
dose of 67.5 Gy in 30 fractions (IRMA 1, 2, and 4) or 70.5 Gy 
in 30 fractions (IRMA 3, 4, and 5) was delivered to primary 
tumor and involved nodes, 60 Gy were delivered to high risk 
and 55.5 Gy to low risk lymph node areas. Static (IMRT) or 
volumetric (VMAT) intensity modulated technique with 
simultaneous integrated boost was used. 
 
Results: 107 patients (median age 56 years, range 30-78, 
UICC stage III: n = 18, IV: n = 89) were included in this 
analysis. IC was performed with Cisplatin + 5-Fluorouracil in 
65 (61%) patients and with Docetaxel + Cisplatin + 5-
Fluorouracil in 42 (39%) cases. Concomitant Cisplatin and 
Cetuximab were administered in 84% and in 16% of patients, 
respectively. 51% (n = 55) of cases were irradiated with step 
& shoot IMRT-SIB technique (7 beams), while 49% (n = 52) of 
patients were irradiated with VMAT-SIB (two arcs) technique. 
During radio-chemotherapy, 23 (21%) patients developed 
mucositis, 12 (11%) G3 dysphagia and 10 (9.3%) G3 
hematological toxicity. Even 1 (0.9%) G4 leukopenia and 3 
(2.8%) G5 (2 neutropenia and one fatal myocardial infarction) 
adverse events were observed. The overall response rate 
after radio-chemotherapy was 82.2%. Two-year local control 
and survival were 64.2% and 64.6% (IRMA 1), respectively, 
57.8% and 56.2% (IRMA 2), 66.4% and 75.5% (IRMA 3), 70.1% 
and 66.7% (IRMA 4), and 76.5% and 82.4% (IRMA 5), 
respectively. 
 
 
 
Conclusion: In our experience moderately hypofractionated 
and accelerated radio-chemotherapy after induction 
chemotherapy was feasible. Intensive patient monitoring and 
supportive strategies during chemoradiation are necessary to 
manage of side effects. 
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Purpose or Objective: To analyse the frequency and severity 
of dysphagia and xerostomia in patients affected by 
nasopharyngeal and oropharyngeal cancers treated by 
intensity-modulated radiotherapy (IMRT) and the correlation 
with volumetric variations and dosimetric data of pharyngeal 
constrictor muscles and parotid glands.  
 
Material and Methods: Fifty patients, who underwent 
adaptive IMRT for nasopharyngeal and oropharyngeal cancers, 
were included in the present study. Eighty-four percent of 
patients (42/50) received concurrent radio-chemotherapy 
and 92% (44/50) were in locally advanced stage. Dose-volume 
parameters related to constrictor muscles (superior 
constrictor muscle, SCM; middle constrictor muscle, MCM; 
inferior constrictor muscle, ICM and whole pharyngeal 
constrictor muscle, CM), and parotid glands were analyzed 
using dose-volume histograms (DVHs). All patients underwent 
replanning CT scan after 5 weeks of radiation therapy and 
the target and OARs were re-contoured on fusion images 
after co-registration. The volumetric variations of pharyngeal 
constrictor muscles and parotid glands were measured. 
Volumetric variations and dose-volume parameters were 
associated to acute and late dysphagia and xerostomia 
according to RTOG score, quality of life questionnaires (PSS-
H&N e QLQ-H&N35), and oesophageal transit . 
 
Results: Volumetric variations and dose-volume parameters 
of pharyngeal constrictor muscles and parotid glands are 
reported in Table 1. Adaptive IMRT achieved a good sparing 
of parotid glands (mean dose 24.9 Gy) and constrictor 
muscles (mean dose 51.2 Gy). Acute dysphagia, was scored as 
grade 0-1 in 18/50 patients (36%) and as grade 2-3 in 32/50 
(64%). Acute xerostomia, was scored as grade 0-1 in 21/50 
patients (42%) and as grade 2-3 in 29/50 (58%). Volumetric 
variations and dose-volume parameters of the constrictor 
muscles and parotid glands did not correlate with acute 
toxicity (p>0.05). At 2 years median follow-up (range 6-67 
months), late dysphagia was scored as grade 0-1 in 40/50 of 
patients (80%) and as grade 2-3 in 10/50 (20%). Late 
xerostomia was scored as grade 0-1 in 42/50 of patients (84%) 
and as grade 2-3 in 8/50 (16%). The analysis of the 
correlation of volumetric variations and dose-volume 
parameters with clinical data (RTOG score for late toxicity, 
quality of life questionnaires and oesophageal transit) is 
ongoing. 
 
 
 
Conclusion: During radiotherapy, pharyngeal constrictor 
muscles and salivary glands underwent volumetric variations. 
Volumetric variations and dosimetric findings did not 
correlate with acute toxicity, probably because of the 
complexity and multifactorial pathogenesis of acute 
dysphagia and xerostomia. The ongoing analysis on the 
correlation of late toxicity data with volumetric variations 
and dose-volume parameters may help in the optimization of 
IMRT treatment planning. 
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